Pharmaceutical care in psychiatry is a specialized area of practice within the field of pharmacy and has been selected for Board Certification in the near future. In order to be maximally effective in this clinical setting, mental health pharmacists must combine their knowledge of psychopharmacology, pathophysiology, laboratory data, standardized assessment tools, and federal Health Care Financing Administration requirements, with non-pharmacological treatments to function within a treatment team concept. This treatment team concept aims at maximizing individual clinical outcomes while at the same time minimizing adverse side effects of the treatment regimen.
Get full access to this article
View all access options for this article.
References
1.
Albani F., Theodore Wh, Washington P. et al : Effect of felbamate on plasma levels of carbrmazepine and its metabolites. Epilepsia1991; 32:130-132.
2.
Anon: Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome. N Engl J Med1993; 328:29-33.
3.
Anon: Recommendation for the immediate withdrawal of patients from treatment with Felbatol(R) (felbamate . FDA Medical Bulletin1994; 24(No. 2):5.
4.
Burdette De & Sackellares Jc : Felbamate pharmacology and use in epilepsy . Clin Neuropharmacol1994; 17:389-402.
5.
Dodson We : Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia1993; 34(Suppl 7):S18-S24.
6.
Fuerst Rh , Graves Nm , Leppik Ie et al: Felbamate increases phenytoin but decreases carbamazepine concentrations. Epilepsia1988 ; 29:488-491.
7.
Gidal Be & Zupanc Ml : Potential pharmacokinetic interaction between felbamate and phenobarbital . Ann Pharmacother1994; 28:455-458.
8.
Graves Nm , Holmes Gb , Fuerst Rh et al: Effect of felbamate on phenytoin and carbamazepine serum concentrations . Epilepsia1989; 30:225-229.
9.
Graves Nm , Ludden Tm , Holmes Gb et al: Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trials . Pharmacotherapy1989a; 9:372-376.
10.
Leppik Ie , Dreifuss Fe , Pledger Gw et al: Felbamate for partial seizures: results of a controlled clinical trial. Neurology1991; 41:1785-1789.
11.
Leppik Ie , Graves N & Devinsky O: New antiepileptic medications. Neurol Clin1993; 11:923-950.
12.
Moyer Tp & Pippenger Ce : Therapeutic drug monitoring. In: Burtis CA & Ashwood ER (Eds): Tietz Textbook of Clinical Chemistry, 2nd ed. WB Saunders Company, Philadelphia, PA, 1994.
13.
Ney Gc, Schaul N., Loughlin J et al: Thrombocytopenia in association with adjunctive felbamate use. Neurology1994; 44:980-981.
14.
Personal Communication: James C. Costin, MD, Research and Development, Wallace Laboratories, August 3, 1994a.
15.
Personal Communication: James C. Costin, MD, Research and Development, Wallace Laboratories, September 21, 1994b.
16.
Product Information: Felbatol(R), felbamate. Wallace Laboratories, Cranbury, New Jersey, 1995.
Rho Jm, Donevan Ds & Rogawski Ma : Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acid A receptors. Ann Neurol1994; 35:229-234.
19.
Romanyshyn La , Wagner Mc, Wichmann Jk: Determination of valproate in the presence of felbamate in human plasma by narrow bore capillary gas chromatography . WB Saunders Company, Philadelphia, PA, 1994.
20.
Theodore Wh , Raubertas Rf , Porter Rj et al: Felbamate: a clinical trial for complex partial seizures. Epilepsia1991; 32:392-397.
21.
Tisdel Ka , Israel Ds & Kolb Kw : Warfarin-felbamate interaction: first report . Ann Pharmacother1994; 28:805.
22.
Wagner Ml , Graves Nm , Leppik Ie et al: The effect of felbamate on valproic acid disposition (abstract . Pharmacotherapy1992; 12:260.
23.
Wagner Ml , Graves Nm , Marienau K.: Discontinuation of phenytoin and carbamazepine in patients recieving felbamate.Epilepsia1991; 32:398-406.
24.
Wagner Ml , Graves Nm , Marienau K. et al: Discontinuation of phenytoin and carbamazepine in patients receiving felbamate . Epilepsia1991; 32:398-406.
25.
Wilensky Aj , Friel Pn, Ojemann LM et al: Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. Epilepsia1985; 26:602-606.
